J. Goldman & CO LP Elevation Oncology, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
4Shares Held
2.67MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY2.49MShares$896,4890.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL174KShares$62,6890.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ2KShares$7200.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.39M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...